Stifel Nicolaus Raises Deciphera Pharmaceuticals (NASDAQ:DCPH) Price Target to $23.00

Deciphera Pharmaceuticals (NASDAQ:DCPHFree Report) had its price target boosted by Stifel Nicolaus from $22.00 to $23.00 in a research report report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock.

DCPH has been the subject of several other reports. HC Wainwright lifted their price target on shares of Deciphera Pharmaceuticals from $25.00 to $30.00 and gave the company a buy rating in a report on Tuesday, October 31st. Jonestrading raised shares of Deciphera Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, October 31st. JPMorgan Chase & Co. reaffirmed a neutral rating and issued a $14.00 price target on shares of Deciphera Pharmaceuticals in a report on Monday, November 20th. Finally, Piper Sandler raised shares of Deciphera Pharmaceuticals from a neutral rating to an overweight rating and lifted their price target for the company from $18.00 to $23.00 in a report on Monday, October 30th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $22.60.

Read Our Latest Stock Report on DCPH

Deciphera Pharmaceuticals Stock Performance

DCPH opened at $15.73 on Wednesday. The company has a 50-day moving average of $15.06 and a 200-day moving average of $13.57. The company has a market capitalization of $1.26 billion, a P/E ratio of -6.87 and a beta of 0.36. Deciphera Pharmaceuticals has a 1-year low of $9.90 and a 1-year high of $17.69.

Deciphera Pharmaceuticals (NASDAQ:DCPHGet Free Report) last released its earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 47.69%. The company had revenue of $48.30 million during the quarter, compared to the consensus estimate of $45.93 million. During the same quarter in the previous year, the firm earned ($0.60) EPS. The company’s revenue was up 32.9% on a year-over-year basis. As a group, sell-side analysts expect that Deciphera Pharmaceuticals will post -2.27 earnings per share for the current fiscal year.

Insider Transactions at Deciphera Pharmaceuticals

In other news, EVP Matthew L. Sherman sold 2,435 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $14.47, for a total value of $35,234.45. Following the completion of the sale, the executive vice president now directly owns 94,079 shares of the company’s stock, valued at approximately $1,361,323.13. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 4.43% of the company’s stock.

Institutional Trading of Deciphera Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its stake in shares of Deciphera Pharmaceuticals by 96.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after acquiring an additional 997 shares during the period. Quest Partners LLC bought a new stake in shares of Deciphera Pharmaceuticals in the 4th quarter worth approximately $30,000. Lazard Asset Management LLC bought a new stake in shares of Deciphera Pharmaceuticals in the 1st quarter worth approximately $57,000. Compass Wealth Management LLC bought a new stake in shares of Deciphera Pharmaceuticals in the 4th quarter worth approximately $70,000. Finally, Advisor Group Holdings Inc. raised its holdings in shares of Deciphera Pharmaceuticals by 78.0% in the 4th quarter. Advisor Group Holdings Inc. now owns 4,331 shares of the company’s stock worth $71,000 after purchasing an additional 1,898 shares in the last quarter. 70.96% of the stock is owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Company Profile

(Get Free Report)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.

Further Reading

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.